{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:59:01Z","timestamp":1787180341885,"version":"build-2736575974"},"reference-count":133,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Neurological and ophthalmological neurodegenerative diseases in large part share underlying biology and pathophysiology. Despite extensive preclinical research on neuroprotection that in many cases bridges and unifies both fields, only a handful of neuroprotective therapies have succeeded clinically in either.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main body<\/jats:title><jats:p>Understanding the commonalities among brain and neuroretinal neurodegenerations can help develop innovative ways to improve translational success in neuroprotection research and emerging therapies. To do this, analysis of why translational research in neuroprotection fails necessitates addressing roadblocks at basic research and clinical trial levels. These include optimizing translational approaches with respect to biomarkers, therapeutic targets, treatments, animal models, and regulatory pathways.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The common features of neurological and ophthalmological neurodegenerations are useful for outlining a path forward that should increase the likelihood of translational success in neuroprotective therapies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.964197","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T07:16:36Z","timestamp":1660288596000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Neuroprotection in neurodegenerations of the brain and eye: Lessons from the past and directions for the future"],"prefix":"10.3389","volume":"13","author":[{"given":"Leonard A.","family":"Levin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Patrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozhat B.","family":"Choudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najam A.","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40035-017-0096-2","article-title":"Disease modification and neuroprotection in neurodegenerative disorders","volume":"6","author":"Cummings","year":"2017","journal-title":"Transl Neurodegener."},{"key":"B2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/ICU.0000000000000558","article-title":"Retinal neuroprotection: current strategies and future directions","volume":"30","author":"Wubben","year":"2019","journal-title":"Curr Opin Ophthalmol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40135-020-00259-5","article-title":"Protect, repair, and regenerate: towards restoring vision in glaucoma","volume":"8","author":"Wareham","year":"2020","journal-title":"Curr Ophthalmol Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.22608\/APO.2018299","article-title":"Neuroprotection in optic neuropathy","volume":"7","author":"Levin","year":"2018","journal-title":"Asia Pac J Ophthalmol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"581136","DOI":"10.3389\/fcell.2020.581136","article-title":"On the generation and regeneration of retinal ganglion cells","volume":"8","author":"Oliveira-Valenca","year":"2020","journal-title":"Front Cell Dev Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.11648\/j.ijovs.20170202.11","article-title":"Ocular hypertension and glaucoma: a review and current perspectives","volume":"2","author":"Sharif","year":"2017","journal-title":"Int J Ophthalmol Vis Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1089\/jop.2017.0125","article-title":"iDrugs and idevices discovery research: preclinical assays, techniques, and animal model studies for ocular hypotensives and neuroprotectants","volume":"34","author":"Sharif","year":"2018","journal-title":"J Ocul Pharmacol Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.4103\/1673-5374.235017","article-title":"Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision","volume":"13","author":"Sharif","year":"2018","journal-title":"Neural Regen Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1001\/archneur.64.6.794","article-title":"Neuroprotection: challenges and opportunities","volume":"64","author":"Faden","year":"2007","journal-title":"Arch Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ajo.2009.03.029","article-title":"Neuroprotection: extrapolating from neurologic diseases to the eye","volume":"148","author":"Danesh-Meyer","year":"2009","journal-title":"Am J Ophthalmol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41593-018-0236-8","article-title":"Animal models of neurodegenerative diseases","volume":"21","author":"Dawson","year":"2018","journal-title":"Nat Neurosci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1111\/j.1582-4934.2008.00402.x","article-title":"Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling","volume":"12","author":"Gorman","year":"2008","journal-title":"J Cell Mol Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/ceo.13336","article-title":"Neuroprotection in glaucoma: recent advances and clinical translation","volume":"47","author":"Guymer","year":"2019","journal-title":"Clin Exp Ophthalmol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1167\/tvst.9.7.17","article-title":"Cognitive impairment and lamina cribrosa thickness in primary open-angle glaucoma","volume":"9","author":"Lee","year":"2020","journal-title":"Transl Vis Sci Technol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40265-020-01428-3","article-title":"Therapeutic options in hereditary optic neuropathies","volume":"81","author":"Amore","year":"2021","journal-title":"Drugs."},{"key":"B16","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3389\/fnins.2018.00834","article-title":"The role of endogenous neuroprotective mechanisms in the prevention of retinal ganglion cells degeneration","volume":"12","author":"Pietrucha-Dutczak","year":"2018","journal-title":"Front Neurosci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/02713683.2019.1663385","article-title":"Neuroprotection in glaucoma: towards clinical trials and precision medicine","volume":"45","author":"Khatib","year":"2020","journal-title":"Curr Eye Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1167\/iovs.12-11055","article-title":"The effect of the oral PKC beta inhibitor ruboxistaurin on vision loss in two phase 3 studies","volume":"54","author":"Sheetz","year":"2013","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ajo.2005.03.058","article-title":"Prophylaxis for second eye involvement in leber hereditary optic neuropathy: an open-labeled, nonrandomized multicenter trial of topical brimonidine purite","volume":"140","author":"Newman","year":"2005","journal-title":"Am J Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ophtha.2020.12.012","article-title":"Efficacy and safety of intravitreal gene therapy for leber hereditary optic neuropathy treated within 6 months of disease onset","volume":"128","author":"Newman","year":"2021","journal-title":"Ophthalmology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.ophtha.2018.06.017","article-title":"Oral memantine for the treatment of glaucoma: design and results of 2 randomized, placebo-controlled, phase 3 studies","volume":"125","author":"Weinreb","year":"2018","journal-title":"Ophthalmology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/s41433-018-0050-2","article-title":"Neuroprotective agents in the management of glaucoma","volume":"32","author":"Nucci","year":"2018","journal-title":"Eye."},{"key":"B23","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ophtha.2011.11.003","article-title":"Glaucoma 2.0: neuroprotection. neuroregeneration, neuroenhancement","volume":"119","author":"Chang","year":"2012","journal-title":"Ophthalmology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1001\/archophthalmol.2009.9","article-title":"Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review","volume":"127","author":"Saylor","year":"2009","journal-title":"Arch Ophthalmol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00417-005-0102-8","article-title":"Efficacy and tolerability of 0","volume":"244","author":"Wilhelm","year":"2006","journal-title":"Arch Clin Exp Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ajo.2010.09.026","article-title":"A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-pressure glaucoma treatment study","volume":"151","author":"Krupin","year":"2011","journal-title":"Am J Ophthalmol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ajo.2011.06.015","article-title":"Clinical evidence for neuroprotection in glaucoma","volume":"152","author":"Cordeiro","year":"2011","journal-title":"Am J Ophthalmol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.cell.2017.10.011","article-title":"Edaravone: a new drug approved for ALS","volume":"171","author":"Rothstein","year":"2017","journal-title":"Cell."},{"key":"B29","volume-title":"FDA-Approved Treatments for Alzheimer's","year":"2019"},{"key":"B30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval","volume":"12","author":"Tolar","year":"2020","journal-title":"Alzheimers Res Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"eaba1659","DOI":"10.1126\/scitranslmed.aba1659","article-title":"Promising disease-modifying therapies for Parkinson's disease","volume":"11","author":"Dawson","year":"2019","journal-title":"Sci Transl Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e12050","DOI":"10.1002\/trc2.12050","article-title":"Alzheimer's disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B33","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1080\/13543784.2020.1795127","article-title":"Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives","volume":"29","author":"Imbimbo","year":"2020","journal-title":"Expert Opin Investig Drugs."},{"key":"B34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamaneurol.2019.3762","article-title":"Minocycline at 2 different dosages vs placebo for patients with mild Alzheimer disease: a randomized clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","article-title":"Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer Disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials","volume":"77","author":"Wessels","year":"2020","journal-title":"JAMA Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S1474-4422(19)30485-5","article-title":"Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial","volume":"19","author":"Chataway","year":"2020","journal-title":"Lancet Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"591","DOI":"10.7326\/M19-2534","article-title":"Isradipine versus placebo in early parkinson disease: a randomized trial","volume":"172","author":"Parkinson","year":"2020","journal-title":"Ann Intern Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S1474-4422(13)70221-7","article-title":"Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial","volume":"12","author":"Cudkowicz","year":"2013","journal-title":"Lancet Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/ene.12344","article-title":"A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis","volume":"21","author":"Lenglet","year":"2014","journal-title":"Eur J Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41231-019-0050-7","article-title":"Lost in translation: the valley of death across preclinical and clinical divide \u2013 identification of problems and overcoming obstacles","volume":"4","author":"Seyhan","year":"2019","journal-title":"Transl Med Commun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.tips.2017.10.003","article-title":"The academic-industrial complexity: failure to launch","volume":"38","author":"Levin","year":"2017","journal-title":"Trends Pharmacol Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1167\/iovs.03-0566","article-title":"Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures","volume":"45","author":"Hare","year":"2004","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1167\/iovs.03-0567","article-title":"Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: structural measures","volume":"45","author":"Hare","year":"2004","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fnagi.2017.00068","article-title":"ALS clinical trials review: 20 years of failure. are we any closer to registering a new treatment?","volume":"9","author":"Petrov","year":"2017","journal-title":"Front Aging Neurosci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3389\/fneur.2017.00521","article-title":"Shortcomings in the current amyotrophic lateral sclerosis trials and potential solutions for improvement","volume":"8","author":"Katyal","year":"2017","journal-title":"Front Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/ijms17060904","article-title":"Neuroprotective and therapeutic strategies against parkinson's disease: recent perspectives","volume":"17","author":"Sarkar","year":"2016","journal-title":"Int J Mol Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1001\/jama.2010.463","article-title":"Lost in translation: bumps in the road between bench and bedside","volume":"303","author":"Levin","year":"2010","journal-title":"JAMA."},{"key":"B48","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13063-017-1870-2","article-title":"Why clinical trial outcomes fail to translate into benefits for patients","volume":"18","author":"Heneghan","year":"2017","journal-title":"Trials."},{"key":"B49","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.coph.2012.08.005","article-title":"Solving the lost in translation problem: improving the effectiveness of translational research","volume":"13","author":"Ergorul","year":"2013","journal-title":"Curr Opin Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fbioe.2016.00043","article-title":"Lost in translation: the gap in scientific advancements and clinical application","volume":"4","author":"Fernandez-Moure","year":"2016","journal-title":"Front Bioeng Biotechnol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1523\/JNEUROSCI.3882-16.2017","article-title":"Axonal degeneration in retinal ganglion cells is associated with a membrane polarity-sensitive redox process","volume":"37","author":"Almasieh","year":"2017","journal-title":"J Neurosci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev-neuro-071714-034120","article-title":"The types of retinal ganglion cells: current status and implications for neuronal classification","volume":"38","author":"Sanes","year":"2015","journal-title":"Annu Rev Neurosci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1523\/JNEUROSCI.1061-19.2019","article-title":"An annotated journey through modern visual neuroscience","volume":"40","author":"Trenholm","year":"2020","journal-title":"J Neurosci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"92696","DOI":"10.1016\/j.ophtha.2017.02.017","article-title":"Special commentary: early clinical development of cell replacement therapy: considerations for the national eye institute audacious goals initiative","volume":"124","author":"Levin","year":"2017","journal-title":"Ophthalmology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"10472","DOI":"10.1038\/ncomms10472","article-title":"Transplanted neurons integrate into adult retinas and respond to light","volume":"7","author":"Venugopalan","year":"2016","journal-title":"Nat Commun."},{"key":"B56","doi-asserted-by":"publisher","first-page":"7842","DOI":"10.1167\/iovs.11-7895","article-title":"Glaucoma research community and FDA look to the future, II: NEI\/FDA glaucoma clinical trial design and endpoints symposium: measures of structural change and visual function","volume":"52","author":"Weinreb","year":"2011","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"100875","DOI":"10.1016\/j.preteyeres.2020.100875","article-title":"Discovery and clinical translation of novel glaucoma biomarkers","volume":"80","author":"Beykin","year":"2021","journal-title":"Prog Retin Eye Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mus.24979","article-title":"ALS biomarkers for therapy development: state of the field and future directions","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle Nerve."},{"key":"B59","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41582-019-0155-7","article-title":"Emerging therapies in Parkinson disease - repurposed drugs and new approaches","volume":"15","author":"Elkouzi","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.neuron.2019.11.006","article-title":"Single-cell profiles of retinal ganglion cells differing in resilience to injury reveal neuroprotective genes","volume":"104","author":"Tran","year":"2019","journal-title":"Neuron."},{"key":"B61","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.exer.2015.06.005","article-title":"The non-human primate experimental glaucoma model","volume":"141","author":"Burgoyne","year":"2015","journal-title":"Exp Eye Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/ilar\/ilx009","article-title":"Nonhuman primate studies to advance vision science and prevent blindness","volume":"58","author":"Mustari","year":"2017","journal-title":"ILAR J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fnins.2015.00064","article-title":"Lessons from the analysis of nonhuman primates for understanding human aging and neurodegenerative diseases","volume":"9","author":"Verdier","year":"2015","journal-title":"Front Neurosci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/ilar\/ilx021","article-title":"Nonhuman primate models of neurodegenerative disorders","volume":"58","author":"Emborg","year":"2017","journal-title":"ILAR J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/164_2016_20","article-title":"Translational pharmacology in glaucoma neuroprotection","volume":"242","author":"Levin","year":"2017","journal-title":"Handb Exp Pharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"xv","DOI":"10.1016\/j.ajo.2018.04.012","article-title":"Retinal neuroprotection: overcoming the translational roadblocks","volume":"192","author":"Wubben","year":"2018","journal-title":"Am J Ophthalmol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.bcp.2013.08.026","article-title":"Biomarkers in pharmacology and drug discovery","volume":"87","author":"Anderson","year":"2014","journal-title":"Biochem Pharmacol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3109\/02713683.2013.827211","article-title":"Mediator lipidomics in ophthalmology: targets for modulation in inflammation, neuroprotection and nerve regeneration","volume":"38","author":"Gordon","year":"2013","journal-title":"Curr Eye Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1152\/physrev.00011.2017","article-title":"Neuronal cell death","volume":"98","author":"Fricker","year":"2018","journal-title":"Physiol Rev."},{"key":"B70","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.1523\/JNEUROSCI.2752-18.2019","article-title":"Regulation of neuronal survival and axon growth by a perinuclear camp compartment","volume":"39","author":"Boczek","year":"2019","journal-title":"J Neurosci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fnmol.2017.00187","article-title":"The endoplasmic reticulum unfolded protein response in neurodegenerative disorders and its potential therapeutic significance","volume":"10","author":"Remondelli","year":"2017","journal-title":"Front Mol Neurosci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/febs.14522","article-title":"ER stress and unfolded protein response in ocular health and disease","volume":"286","author":"Kroeger","year":"2019","journal-title":"FEBS J."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.cub.2019.05.011","article-title":"Opposing effects of growth and differentiation factors in cell-fate specification","volume":"29","author":"Chang","year":"2019","journal-title":"Curr Biol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"8397521","DOI":"10.1155\/2019\/8397521","article-title":"Therapeutic strategies for attenuation of retinal ganglion cell injury in optic neuropathies: concepts in translational research and therapeutic implications","volume":"2019","author":"Fu","year":"2019","journal-title":"Biomed Res Int."},{"key":"B75","doi-asserted-by":"publisher","first-page":"9329310","DOI":"10.1155\/2020\/9329310","article-title":"Innovative IOP-independent neuroprotection and neuroregeneration strategies in the pipeline for glaucoma","volume":"2020","author":"Tsai","year":"2020","journal-title":"J Ophthalmol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/WCO.0000000000000777","article-title":"Neuro-protection and neuro-regeneration of the optic nerve: recent advances and future directions","volume":"33","author":"Gokoffski","year":"2020","journal-title":"Curr Opin Neurol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pharmthera.2016.06.004","article-title":"Emerging mitochondrial therapeutic targets in optic neuropathies","volume":"165","author":"Lopez Sanchez","year":"2016","journal-title":"Pharmacol Ther."},{"key":"B78","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/jnc.14112","article-title":"Fine-tuning PERK signaling for neuroprotection","volume":"142","author":"Halliday","year":"2017","journal-title":"J Neurochem."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.4103\/1673-5374.237108","article-title":"Neuroprotection by immunomodulatory agents in animal models of Parkinson's disease","volume":"13","author":"Martinez","year":"2018","journal-title":"Neural Regen Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev-cellbio-040320-120625","article-title":"Developing therapies for neurodegenerative disorders: insights from protein aggregation and cellular stress responses","volume":"36","author":"Mallucci","year":"2020","journal-title":"Annu Rev Cell Dev Biol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41582-020-0344-4","article-title":"Parkinson disease and the immune system - associations, mechanisms and therapeutics","volume":"16","author":"Tan","year":"2020","journal-title":"Nat Rev Neurol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.exer.2016.12.005","article-title":"Neuroprotection for glaucoma: requirements for clinical translation","volume":"157","author":"Levin","year":"2017","journal-title":"Exp Eye Res."},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041615","article-title":"Targeting for success: demonstrating proof-of-concept with mechanistic early phase clinical pharmacology studies for disease-modification in neurodegenerative disorders","volume":"22","author":"Vissers","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B84","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-030-05542-4_2","article-title":"The role of biomarkers in Alzheimer's disease drug development","volume":"1118","author":"Cummings","year":"2019","journal-title":"Adv Exp Med Biol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/eye.2016.299","article-title":"Protecting retinal ganglion cells","volume":"31","author":"Khatib","year":"2017","journal-title":"Eye."},{"key":"B86","doi-asserted-by":"publisher","first-page":"41768","DOI":"10.1038\/srep41768","article-title":"Intranasal delivery of a novel amnion cell secretome prevents neuronal damage and preserves function in a mouse multiple sclerosis model","volume":"7","author":"Khan","year":"2017","journal-title":"Sci Rep."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1167\/iovs.18-24096","article-title":"RGC neuroprotection following optic nerve trauma mediated by intranasal delivery of amnion cell secretome","volume":"59","author":"Grinblat","year":"2018","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1146\/annurev-vision-022720-094953","article-title":"Axon regeneration in the mammalian optic nerve","volume":"6","author":"Williams","year":"2020","journal-title":"Annu Rev Vis Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/jnr.24256","article-title":"Neuroinflammation and microglia in glaucoma: time for a paradigm shift","volume":"97","author":"Wei","year":"2019","journal-title":"J Neurosci Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","article-title":"The classical complement cascade mediates CNS synapse elimination","volume":"131","author":"Stevens","year":"2007","journal-title":"Cell."},{"key":"B91","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","article-title":"Complement and microglia mediate early synapse loss in Alzheimer mouse models","volume":"352","author":"Hong","year":"2016","journal-title":"Science."},{"key":"B92","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","article-title":"Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes","volume":"9","author":"Kwon","year":"2020","journal-title":"Transl Neurodegener."},{"key":"B93","doi-asserted-by":"publisher","first-page":"8421","DOI":"10.3390\/ijms21228421","article-title":"Neurodegeneration and inflammation-an interesting interplay in parkinson's disease","volume":"21","author":"Marogianni","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B94","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s12974-020-02024-8","article-title":"The good, the bad, and the opportunities of the complement system in neurodegenerative disease","volume":"17","author":"Schartz","year":"2020","journal-title":"J Neuroinflammation."},{"key":"B95","doi-asserted-by":"publisher","first-page":"55001","DOI":"10.1088\/1741-2560\/6\/5\/055001","article-title":"Electrical activity enhances neuronal survival and regeneration","volume":"6","author":"Corredor","year":"2009","journal-title":"J Neural Eng."},{"key":"B96","doi-asserted-by":"publisher","first-page":"7734","DOI":"10.1523\/JNEUROSCI.5288-11.2012","article-title":"Soluble adenylyl cyclase activity is necessary for retinal ganglion cell survival and axon growth","volume":"32","author":"Corredor","year":"2012","journal-title":"J Neurosci."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/nn.4340","article-title":"Neural activity promotes long-distance, target-specific regeneration of adult retinal axons","volume":"19","author":"Lim","year":"2016","journal-title":"Nat Neurosci."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1016\/j.ebiom.2015.10.025","article-title":"Muscle A-kinase anchoring protein-alpha is an injury-specific signaling scaffold required for neurotrophic- and cyclic adenosine monophosphate-mediated survival","volume":"2","author":"Wang","year":"2015","journal-title":"EBioMedicine."},{"key":"B99","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.brs.2011.07.007","article-title":"Restoration of vision after optic nerve lesions with noninvasive transorbital alternating current stimulation: a clinical observational study","volume":"4","author":"Fedorov","year":"2011","journal-title":"Brain Stimul."},{"key":"B100","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3233\/RNN-2011-0624","article-title":"Non-invasive alternating current stimulation improves vision in optic neuropathy","volume":"29","author":"Sabel","year":"2011","journal-title":"Restor Neurol Neurosci."},{"key":"B101","doi-asserted-by":"publisher","first-page":"e0156134","DOI":"10.1371\/journal.pone.0156134","article-title":"Alternating current stimulation for vision restoration after optic nerve damage: a randomized clinical trial","volume":"11","author":"Gall","year":"2016","journal-title":"PLoS ONE."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.brs.2015.06.006","article-title":"Repetitive transcorneal alternating current stimulation reduces brain idling state after long-term vision loss","volume":"8","author":"Sergeeva","year":"2015","journal-title":"Brain Stimul."},{"key":"B103","doi-asserted-by":"publisher","first-page":"17940","DOI":"10.1038\/s41598-021-96971-8","article-title":"Spacetime in the brain: rapid brain network reorganization in visual processing and recovery","volume":"11","author":"Wu","year":"2021","journal-title":"Sci Rep."},{"key":"B104","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1212\/WNL.0000000000000672","article-title":"Brain functional connectivity network breakdown and restoration in blindness","volume":"83","author":"Bola","year":"2014","journal-title":"Neurology."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/jnci\/djt209","article-title":"From bench to bedside: lessons learned in translating preclinical studies in cancer drug development","volume":"105","author":"Lieu","year":"2013","journal-title":"J Natl Cancer Inst."},{"key":"B106","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JAD-179901","article-title":"Clinical trials for disease-modifying therapies in alzheimer's disease: a primer, lessons learned, and a blueprint for the future","volume":"64","author":"Cummings","year":"2018","journal-title":"J Alzheimers Dis."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.45881","article-title":"Silicone oil-induced ocular hypertension and glaucomatous neurodegeneration in mouse","volume":"8","author":"Zhang","year":"2019","journal-title":"Elife."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br J Pharmacol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/bjophthalmol-2018-312724","article-title":"Recent advances in genetically modified animal models of glaucoma and their roles in drug repositioning","volume":"103","author":"Harada","year":"2019","journal-title":"Br J Ophthalmol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/sj.eye.6701576","article-title":"Animal models of optic nerve diseases","volume":"18","author":"Levkovitch-Verbin","year":"2004","journal-title":"Eye."},{"key":"B111","doi-asserted-by":"publisher","first-page":"582039","DOI":"10.1155\/2014\/582039","article-title":"Highights in the history of epilepsy: the last 200 years","volume":"2014","author":"Magiorkinis","year":"2014","journal-title":"Epilepsy Res Treat."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1007\/s11064-017-2275-z","article-title":"The national institute of neurological disorders and stroke (NINDS) epilepsy therapy screening program (ETSP)","volume":"42","author":"Kehne","year":"2017","journal-title":"Neurochem Res."},{"key":"B113","article-title":"BEST (Biomarkers, EndpointS, and other Tools) Resource","year":"2016"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1093\/brain\/awx088","article-title":"Real-time imaging of single neuronal cell apoptosis in patients with glaucoma","volume":"140","author":"Cordeiro","year":"2017","journal-title":"Brain."},{"key":"B115","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0079-6123(08)01130-8","article-title":"Assessment of neuroprotection in the retina with DARC","volume":"173","author":"Guo","year":"2008","journal-title":"Prog Brain Res."},{"key":"B116","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13024-020-00406-3","article-title":"Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers","volume":"15","author":"Zucchi","year":"2020","journal-title":"Mol Neurodegener."},{"key":"B117","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1212\/WNL.0000000000009559","article-title":"Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS","volume":"95","author":"Benatar","year":"2020","journal-title":"Neurology."},{"key":"B118","doi-asserted-by":"publisher","first-page":"6138132","DOI":"10.1155\/2020\/6138132","article-title":"Current medical therapy and future trends in the management of glaucoma treatment","volume":"2020","author":"Cvenkel","year":"2020","journal-title":"J Ophthalmol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1038\/s41433-021-01570-6","article-title":"Current and novel multi-imaging modalities to assess retinal oxygenation and blood flow","volume":"35","author":"Marino","year":"2021","journal-title":"Eye."},{"key":"B120","doi-asserted-by":"publisher","first-page":"e000429","DOI":"10.1136\/bmjophth-2019-000429","article-title":"Eye-tracking-based visual field analysis (EFA): a reliable and precise perimetric methodology for the assessment of visual field defects","volume":"6","author":"Leitner","year":"2021","journal-title":"BMJ Open Ophthalmol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"100907","DOI":"10.1016\/j.preteyeres.2020.100907","article-title":"Fundus-controlled perimetry (microperimetry): application as outcome measure in clinical trials","volume":"82","author":"Pfau","year":"2021","journal-title":"Prog Retin Eye Res."},{"key":"B122","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41433-020-01286-z","article-title":"Adaptive optics: principles and applications in ophthalmology","volume":"35","author":"Akyol","year":"2021","journal-title":"Eye."},{"key":"B123","article-title":"Improvements to multi-offset adaptive optics scanning laser ophthalmoscopy for in vivo imaging of individual retinal ganglion cell layer neurons in humans","volume-title":"bioRxiv","author":"Gofas-Salas","year":"2021"},{"key":"B124","article-title":"In vivo physiology of foveal retinal ganglion cells in Macaca fascicularis","volume-title":"bioRxiv.","author":"Godat","year":"2022"},{"key":"B125","doi-asserted-by":"publisher","first-page":"eabc1124","DOI":"10.1126\/sciadv.abc1124","article-title":"The optoretinogram reveals the primary steps of phototransduction in the living human eye","volume":"6","author":"Pandiyan","year":"2020","journal-title":"Sci Adv."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.21037\/atm-20-6440","article-title":"Toward a clinical optoretinogram: a review of noninvasive, optical tests of retinal neural function","volume":"9","author":"Jonnal","year":"2021","journal-title":"Anna Translat Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1093\/brain\/awq105","article-title":"Superoxide is an associated signal for apoptosis in axonal injury","volume":"133","author":"Kanamori","year":"2010","journal-title":"Brain."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41467-020-15317-6","article-title":"Optogenetic restoration of retinal ganglion cell activity in the living primate","volume":"11","author":"Mcgregor","year":"2020","journal-title":"Nat Commun."},{"key":"B129","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ogla.2021.12.006","article-title":"Mitochondrial dysfunction in primary open-angle glaucoma characterized by flavoprotein fluorescence at the optic nerve head","volume":"5","author":"Zhou","year":"2021","journal-title":"Ophthalmol Glaucoma"},{"key":"B130","first-page":"3515","article-title":"Flavoprotein fluorescence (FPF) elevation using retinal metabolic analysis correlates with decreased visual acuity in patients with various retinal pathologies","volume":"63","author":"Ahsanuddin","year":"2022","journal-title":"Investigat Ophthalmol Vis Sci."},{"key":"B131","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1167\/iovs.17-22339","article-title":"Report from the NEI\/FDA endpoints workshop on age-related macular degeneration and inherited retinal diseases","volume":"58","author":"Csaky","year":"2017","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B132","doi-asserted-by":"publisher","first-page":"729249","DOI":"10.3389\/fphar.2021.729249","article-title":"Therapeutic drugs and devices for tackling ocular hypertension and glaucoma, and need for neuroprotection and cytoprotective therapies","volume":"12","author":"Sharif","year":"2021"},{"key":"B133","doi-asserted-by":"crossref","DOI":"10.1089\/jop.2022.0046","article-title":"Electrical, electromagnetic, ultrasound wave therapies and electronic implants for neuronal rejuvenation, neuroprotection, axonal regeneration and IOP reduction","volume-title":"J Ocular Pharmacol Therapeutics","author":"Sharif","year":""}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.964197\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T12:12:13Z","timestamp":1676376733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.964197\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":133,"alternative-id":["10.3389\/fneur.2022.964197"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.964197","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"article-number":"964197"}}